BioCentury | Aug 1, 2020
Tools & Techniques

A plasma tau marker gains support for diagnosing Alzheimer’s disease

Two studies published this week advance the search for blood tests for Alzheimer’s disease, but it’s not yet clear how transformative the plasma markers will be. Both studies came to the same conclusion: one form...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

MorphoSys follows Kress’ first big deal with U.S. approval FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Incyte Corp. (NASDAQ:INCY) in combination with lenalidomide to treat patients with relapsed or...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...
BioCentury | Jul 31, 2020
Product Development

COVID-19 antibody treatments could be available in September, ahead of vaccines

COVID-19 antibody therapeutics could be authorized as early as September, with vaccines expected to be available later in the fall, a senior government official said Thursday. In addition to updating the countermeasure timeline, the official...
BioCentury | Jul 28, 2020
Emerging Company Profile

Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round

Kent Hawryluk and Richard DiMarchi are following up on the first two companies they formed together, diabetes-focused Marcadia and MB2, with rare endocrine diseases play MBX Biosciences. Frazier, which led Marcadia Biotech Inc.’s series A...
BioCentury | Jul 23, 2020
Emerging Company Profile

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...
BioCentury | Jul 18, 2020
Product Development

COVID-19 mAb developers weigh master protocols as they set clinical strategies

Drugmakers developing the first crop of COVID-specific mAbs are facing the question of whether to pursue independent, company-sponsored trials or participate in master protocols that have been successful for repurposed drugs during the pandemic. So...
BioCentury | Jul 16, 2020
Product Development

AC Immune’s biggest stock move this year likely to come from tau mAb

The 19% stock bump of neurodegeneration play AC Immune S.A. (NASDAQ:ACIU) on Thursday may have reflected excitement about the target of the company’s anti-tau vaccine for Alzheimer’s disease more than any new information about the...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

NextCure Inc. (NASDAQ:NXTC) said CMO Kevin Heller has resigned, effective Aug. 4, to pursue a new opportunity; the immunotherapy company is searching for a successor. NextCure also said Monday that, based on response data, it...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
Items per page:
1 - 10 of 5996
BioCentury | Aug 1, 2020
Tools & Techniques

A plasma tau marker gains support for diagnosing Alzheimer’s disease

Two studies published this week advance the search for blood tests for Alzheimer’s disease, but it’s not yet clear how transformative the plasma markers will be. Both studies came to the same conclusion: one form...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

MorphoSys follows Kress’ first big deal with U.S. approval FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Incyte Corp. (NASDAQ:INCY) in combination with lenalidomide to treat patients with relapsed or...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...
BioCentury | Jul 31, 2020
Product Development

COVID-19 antibody treatments could be available in September, ahead of vaccines

COVID-19 antibody therapeutics could be authorized as early as September, with vaccines expected to be available later in the fall, a senior government official said Thursday. In addition to updating the countermeasure timeline, the official...
BioCentury | Jul 28, 2020
Emerging Company Profile

Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round

Kent Hawryluk and Richard DiMarchi are following up on the first two companies they formed together, diabetes-focused Marcadia and MB2, with rare endocrine diseases play MBX Biosciences. Frazier, which led Marcadia Biotech Inc.’s series A...
BioCentury | Jul 23, 2020
Emerging Company Profile

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...
BioCentury | Jul 18, 2020
Product Development

COVID-19 mAb developers weigh master protocols as they set clinical strategies

Drugmakers developing the first crop of COVID-specific mAbs are facing the question of whether to pursue independent, company-sponsored trials or participate in master protocols that have been successful for repurposed drugs during the pandemic. So...
BioCentury | Jul 16, 2020
Product Development

AC Immune’s biggest stock move this year likely to come from tau mAb

The 19% stock bump of neurodegeneration play AC Immune S.A. (NASDAQ:ACIU) on Thursday may have reflected excitement about the target of the company’s anti-tau vaccine for Alzheimer’s disease more than any new information about the...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

NextCure Inc. (NASDAQ:NXTC) said CMO Kevin Heller has resigned, effective Aug. 4, to pursue a new opportunity; the immunotherapy company is searching for a successor. NextCure also said Monday that, based on response data, it...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
Items per page:
1 - 10 of 5996